Seikagaku Granted Marketing Approval for JOYCLU Joint Function Improvement Injection

By Julie A. Vetalice

Seikagaku Granted Marketing Approval for JOYCLU Joint Function Improvement Injection

Seikagaku and partner Ono Pharmaceutical announced approval from the Japan Ministry of Health, Labour and Welfare for manufacturing and marketing of JOYCLU® to treat hip and knee osteoarthritis.

The companies jointly submitted the application in 1Q20.

JOYCLU combines hyaluronic acid and the anti-inflammatory drug diclofenac, administered by injection into the joint cavity once every four weeks. JOYCLU is the first joint function improvement agent in Japan indicated for the treatment of osteoarthritis of the hip joint.

Seikagaku will manufacture and market the product, and Ono will be responsible for distribution.

 

Product Labels: Viscosupplement

Tags: Regulatory